{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:05:39Z","timestamp":1783901139369,"version":"3.55.0"},"reference-count":44,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adrenocortical carcinoma (ACC) is a rare cancer that presents significant diagnostic and therapeutic challenges. We analyzed the management and estimated survival of ACC patients in Slovenia over a 17-year period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>Patients registered in the National Cancer Registry and treated from 2000 to 2017 were included. The survival and prognostic factors were assessed using the Kaplan-Meier method and Cox regression, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-eight patients were included in our analysis. At the time of diagnosis, 6%, 42%, 25% and 27% had stage according European Network for the Study of Adrenal Tumors (ENSAT) I, II, III and IV, respectively. Adjuvant treatment with mitotane was assigned to 18 of 34 potentially eligible patients. High-risk patients treated with adjuvant mitotane showed a reduced probability of death, although the difference was not statistically significant. Relapses had numerically higher rate of R1 resection and higher Ki67. Eleven patients underwent first-line therapy with etoposide, doxorubicin, cisplatin and mitotane (EDP-M). Their median progression-free survival was 4.4 months. The median overall survival of entire cohort was 28.9 and the median disease-specific survival (DSS) was 36.2 months. The 5-year DSS rate of ENSAT I, II, III and IV were 100%, 56%, 50% and 0%, respectively. The prognostic value of ENSAT stage and Helsinki score regarding overall survival was confirmed with the multivariate analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The 5-year DSS of our ENSAT II patients was worse than reported in contemporary cohorts. Suboptimal surgery and inconsistent adjuvant therapy with mitotane might have contributed to this outcome. Better outcomes of this rare disease might be accomplished with dedicated teams including various specialties, working towards optimal staging, diagnostic and therapeutic measures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2025-0013","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T13:36:11Z","timestamp":1740663371000},"page":"121-131","source":"Crossref","is-referenced-by-count":0,"title":["Management of adrenocortical carcinoma in Slovenia: a real-life analysis of histopathologic markers, treatment patterns, prognostic factors, and survival"],"prefix":"10.2478","volume":"59","author":[{"given":"Urska","family":"Bokal","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jera","family":"Jeruc","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomaz","family":"Kocjan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana , Ljubljana , Slovenia"},{"name":"Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metka","family":"Volavsek","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janja","family":"Jerebic","sequence":"additional","affiliation":[{"name":"Department of Methodology, Faculty of Organizational Sciences, University of Maribor , Kranj , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matej","family":"Rakusa","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana , Ljubljana , Slovenia"},{"name":"Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Mencinger","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institute of Oncology Ljubljana , Ljubljana , Slovenia"},{"name":"Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"2026071215424734944_j_raon-2025-0013_ref_001","doi-asserted-by":"crossref","unstructured":"Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer 2013; 49: 2579-86. doi: 10.1016\/j.ejca.2013.02.034","DOI":"10.1016\/j.ejca.2013.02.034"},{"key":"2026071215424734944_j_raon-2025-0013_ref_002","doi-asserted-by":"crossref","unstructured":"Calabrese A, Basile V, Puglisi S, Perotti P, Pia A, Saba L, et al. Adjuvant mi-totane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. Eur J Endocrinol 2019; 180: 387-96. doi: 10.1530\/eje-18-0923","DOI":"10.1530\/EJE-18-0923"},{"key":"2026071215424734944_j_raon-2025-0013_ref_003","doi-asserted-by":"crossref","unstructured":"Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger RR, et al. European society of endocrinology clinical practice guidelines on the man-agement of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol 2018; 179: G1-G46. doi: 10.1530\/EJE-18-0608","DOI":"10.1530\/EJE-18-0608"},{"key":"2026071215424734944_j_raon-2025-0013_ref_004","doi-asserted-by":"crossref","unstructured":"Gambella A, Volante M, Papotti M. Histopathologic features of adre-nal cortical carcinoma. Adv Anat Pathol 2023; 30: 34-46. doi:10.1097\/PAP.0000000000000363","DOI":"10.1097\/PAP.0000000000000363"},{"key":"2026071215424734944_j_raon-2025-0013_ref_005","doi-asserted-by":"crossref","unstructured":"Weiss LM. Comparative histologic study of 43 metastasizing and nonme-tastasizing adrenocortical tumors. Am J Surg Pathol 1984; 8:163-9. doi: 10.1097\/00000478-198403000-00001","DOI":"10.1097\/00000478-198403000-00001"},{"key":"2026071215424734944_j_raon-2025-0013_ref_006","doi-asserted-by":"crossref","unstructured":"Duregon E, Cappellesso R, Maffeis V, Zaggia B, Ventura L, Berruti A, et al. Validation of the prognostic role of the \u201cHelsinki Score\u201e in 225 cases of adrenocortical carcinoma. Hum Pathol 2017; 62: 1-7. doi: 10.1016\/j.hum-path.2016.09.035","DOI":"10.1016\/j.humpath.2016.09.035"},{"key":"2026071215424734944_j_raon-2025-0013_ref_007","unstructured":"Phan AT, Grogan RH, Rohren E, Perrier ND. Adrenal cortical carcinoma. In: Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al, editors. AJCC Cancer Staging Manual. 8th edition. New York: Springer; 2016. p. 919-26."},{"key":"2026071215424734944_j_raon-2025-0013_ref_008","doi-asserted-by":"crossref","unstructured":"Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 2009; 155: 243-50. doi: 10.1002\/cncr.24030","DOI":"10.1002\/cncr.24030"},{"key":"2026071215424734944_j_raon-2025-0013_ref_009","doi-asserted-by":"crossref","unstructured":"Terzolo M, Fassnacht M, Perotti P, Libe R, Kastelan D, Lacroix A, et al. Adjuvant mitotane versus surveillance in low-grade, localised adrenocorti-cal carcinoma (ADIUVO): an international, multicentre, open-label, ran-domised, phase 3 trial and observational study. Lancet Diabetes Endocrinol 2023; 11: 720-30. doi: 10.1016\/S2213-8587(23)00193-6","DOI":"10.1016\/S2213-8587(23)00193-6"},{"key":"2026071215424734944_j_raon-2025-0013_ref_010","doi-asserted-by":"crossref","unstructured":"Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012; 366: 2189-97. doi: 10.1056\/NEJMoa1200966","DOI":"10.1056\/NEJMoa1200966"},{"key":"2026071215424734944_j_raon-2025-0013_ref_011","doi-asserted-by":"crossref","unstructured":"Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Ahnert JR, et al. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 2020; 8: e000347. doi: 10.1136\/jitc-2019-000347","DOI":"10.1136\/jitc-2019-000347"},{"key":"2026071215424734944_j_raon-2025-0013_ref_012","doi-asserted-by":"crossref","unstructured":"Campbell MT, Balderrama-Brondani V, Jimenez C, Tamsen G, Marcal LP, Varghese J, et al. Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial. Lancet Oncol 2024; 25: 649-57. doi: 10.1016\/S1470-2045(24)00095-0","DOI":"10.1016\/S1470-2045(24)00095-0"},{"key":"2026071215424734944_j_raon-2025-0013_ref_013","doi-asserted-by":"crossref","unstructured":"Altieri B, Ronchi CL, Kroiss M, Fassnacht M. Next-generation therapies for adrenocortical carcinoma. Best Pract Res Clin Endocrinol Met 2020; 34: 101434. doi: 10.1016\/j.beem.2020.101434","DOI":"10.1016\/j.beem.2020.101434"},{"key":"2026071215424734944_j_raon-2025-0013_ref_014","doi-asserted-by":"crossref","unstructured":"Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haar HR, et al. Adrenocortical carcinomas and malignant pheochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and fol-low-up. Ann Oncol 2020; 31: 1476-90. doi: 10.1016\/j.annonc.2020.08.2099","DOI":"10.1016\/j.annonc.2020.08.2099"},{"key":"2026071215424734944_j_raon-2025-0013_ref_015","doi-asserted-by":"crossref","unstructured":"Beuschlein F, Weigel J, Saeger W, Kroiss M, Wild V, Daffara F, et al. Major prognostic role of Ki67 in localised adrenocortical carcinoma after com-plete resection. J Clin Endocrinol Metab 2015; 100: 841-9. doi: 10.1210\/jc.2014-3182","DOI":"10.1210\/jc.2014-3182"},{"key":"2026071215424734944_j_raon-2025-0013_ref_016","doi-asserted-by":"crossref","unstructured":"Libe R, Borget I, Ronchi CL, Zaggia B, Kroiss M, Kerkhofs T, et al. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European network for the study of adrenal tumor (ENSAT) study. Ann Oncol 2015; 26: 2119-25. doi: 10.1093\/annonc\/mdv329","DOI":"10.1093\/annonc\/mdv329"},{"key":"2026071215424734944_j_raon-2025-0013_ref_017","doi-asserted-by":"crossref","unstructured":"Bisceglia M, Ludovico O, Di Mattia A, Ben-Dor D, Sandbank J, Pasquinelli G, et al. Adrenocortical oncocytic tumors: report of 10 cases and review of the literature. Int J Surg Pathol 2004; 12: 231-43. doi: 10.1177\/106689690401200304","DOI":"10.1177\/106689690401200304"},{"key":"2026071215424734944_j_raon-2025-0013_ref_018","doi-asserted-by":"crossref","unstructured":"Erickson LA. Challenges in surgical pathology of adrenocortical tumours. Histopathology 2018; 72: 82-96. doi: 10.1111\/his.13255","DOI":"10.1111\/his.13255"},{"key":"2026071215424734944_j_raon-2025-0013_ref_019","doi-asserted-by":"crossref","unstructured":"Laubert T, Habermann JK, Hemmelmann C, Kleemann M, Oevermann E, Bouchard R, et al. Metachronous metastasis-and survival-analysis show prognostic importance of lymphadenectomy for colon carcinomas. BMC Gastroenterol 2012; 12: 24. doi: 10.1186\/1471-230X-12-24","DOI":"10.1186\/1471-230X-12-24"},{"key":"2026071215424734944_j_raon-2025-0013_ref_020","doi-asserted-by":"crossref","unstructured":"Didolkar MS, Bescher RA, Elias EG, Moore RH. Natural history of adre-nal cortical carcinoma: a clinicopathologic study of 42 patients. Cancer 1981; 47: 2153-61. doi: 10.1002\/1097-0142(19810501)47:9<3C2153:aid-cncr2820470908>3E3.0.co;2-6","DOI":"10.1002\/1097-0142(19810501)47:9<2153::AID-CNCR2820470908>3.0.CO;2-6"},{"key":"2026071215424734944_j_raon-2025-0013_ref_021","doi-asserted-by":"crossref","unstructured":"Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993; 72: 3145-55. doi: 10.1002\/1097-0142(19931201)72:11<3145::AID-CNCR2820721105>3.0.CO;2-N","DOI":"10.1002\/1097-0142(19931201)72:11<3145::AID-CNCR2820721105>3.0.CO;2-N"},{"key":"2026071215424734944_j_raon-2025-0013_ref_022","doi-asserted-by":"crossref","unstructured":"Souteiro P, Donato S, Costa C, Pereira CA, Simoes-Pereira J, Oliveira J, et al. Diagnosis, treatment and survival analysis of adrenocortial carcinomas: a multicentric study. Hormones 2020; 19: 197-203. doi: 10.1007\/s42000-019-00161-1","DOI":"10.1007\/s42000-019-00161-1"},{"key":"2026071215424734944_j_raon-2025-0013_ref_023","doi-asserted-by":"crossref","unstructured":"Kostiainen I, Hakaste L, Kejo P, Parviainen H, Laine T, L\u00f6yttyniemi E, et al. Adrenocortical carcinoma: presentation and outcome of a contemporary patient series. Endocrine 2019; 65: 166-74. doi:10.1007\/s12020-019-01918-9","DOI":"10.1007\/s12020-019-01918-9"},{"key":"2026071215424734944_j_raon-2025-0013_ref_024","doi-asserted-by":"crossref","unstructured":"Margonis GA, Kim Y, Prescott JD, Tran TB, Postlewait LM, Maithel SK, et al. Adrenocortical carcinoma: Impact of surgical margin status on long-term outcomes. Ann Surg Oncol 2016; 23: 134-41. doi: 10.1245\/s10434-015-4803-x","DOI":"10.1245\/s10434-015-4803-x"},{"key":"2026071215424734944_j_raon-2025-0013_ref_025","doi-asserted-by":"crossref","unstructured":"Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metabol 2009; 23: 273-89. doi: 10.1016\/j.beem.2008.10.008","DOI":"10.1016\/j.beem.2008.10.008"},{"key":"2026071215424734944_j_raon-2025-0013_ref_026","doi-asserted-by":"crossref","unstructured":"Puglisi S, Calabrese A, Ferrau F, Violi MA, Lagana M, Grisanti S, et al. New findings on presentation and outcome of patients with adrenocortical can-cer: results from a national cohort study. J Clin Endocrinol Metab 2023; 108: 2517-25. doi: 10.1210\/clinem\/dgad199","DOI":"10.1210\/clinem\/dgad199"},{"key":"2026071215424734944_j_raon-2025-0013_ref_027","doi-asserted-by":"crossref","unstructured":"Chortis V, Taylor AE, Schneider P, Tomlinson JW, Hughes BA, O\u2019Neil DM, et al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5\u03b1 -reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab 2013; 98: 161-71. doi: 10.1210\/jc.2012-2851","DOI":"10.1210\/jc.2012-2851"},{"key":"2026071215424734944_j_raon-2025-0013_ref_028","doi-asserted-by":"crossref","unstructured":"Henning JE, Deutschbein T, Altieri B, Steinhauer S, Kircher S, Sbiera S, et al Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicen-tre study of efficacy and predictive factors. J Clni Endocrinol Metab 2017; 102: 4323-32. doi: 10.1210\/jc.2017-01624","DOI":"10.1210\/jc.2017-01624"},{"key":"2026071215424734944_j_raon-2025-0013_ref_029","doi-asserted-by":"crossref","unstructured":"Kroiss M, Deutschbein T, Schl\u00f6telburg W, Ronchi CL, Hescot S, K\u00f6rbl D, et al. Treatment of refractory adrenocortical carcinoma with thalidomide: analysis of 27 patients from the European Network for the Study of Adrenal Tumours registry. Exp Clin Endocrinol Diabetes 2019; 127: 578-84. doi: 10.1055\/a-0747-5571","DOI":"10.1055\/a-0747-5571"},{"key":"2026071215424734944_j_raon-2025-0013_ref_030","doi-asserted-by":"crossref","unstructured":"Owen DH, Patel S, Wei L, Phay JE, Shirley LA, Kirschner LS, et al. Metastatic adrenocortical carcinoma: a single institutional experience. Horm Cancer 2019; 10: 161-7. doi: 10.1007\/s12672-019-00367-0","DOI":"10.1007\/s12672-019-00367-0"},{"key":"2026071215424734944_j_raon-2025-0013_ref_031","doi-asserted-by":"crossref","unstructured":"Hescot S, Debien V, Hadoux J, Drui D, Haissaguerre M, de la Fouchardiere C, et al. Outcome of adrenocortical carcinoma patients included in early phase clinical trials: Results from the French network ENDOCAN-COMETE. Eur J Cancer 2023; 189: 112917. doi: 10.1016\/j.ejca.2023.05.006","DOI":"10.1016\/j.ejca.2023.05.006"},{"key":"2026071215424734944_j_raon-2025-0013_ref_032","doi-asserted-by":"crossref","unstructured":"Kimpel O, Schindler P, Schmidt-Pennington L, Altieri B, Megerle F, Haak H. et al. Efficacy and safety of radiation therapy in advanced adrenocortical car-cinoma. Br J Cancer 2023; 128: 586-93. doi: 10.1038\/s41416-022-02082-0","DOI":"10.1038\/s41416-022-02082-0"},{"key":"2026071215424734944_j_raon-2025-0013_ref_033","doi-asserted-by":"crossref","unstructured":"Calabrese A, Puglisi S, Borin C, Basile V, Perotti P, Pia A, et al. The manage-ment of postoperative disease recurrence in patients with adrenocortical carcinoma: a retrospective study in 106 patients. Eur J Endocrinol 2023; 188: 118-24. doi: 10.1093\/ejendo\/lvad002","DOI":"10.1093\/ejendo\/lvad002"},{"key":"2026071215424734944_j_raon-2025-0013_ref_034","doi-asserted-by":"crossref","unstructured":"Pennanen M, Heiskanen I, Sane T, Remes S, Mustonen H, Haglund C, et al. Helsinki score-a novel model for prediction of metastases in adreno-cortical carcinomas. Hum Pathol 2015; 46: 404-10. doi: 10.1016\/j.hump-ath.2014.11.015","DOI":"10.1016\/j.humpath.2014.11.015"},{"key":"2026071215424734944_j_raon-2025-0013_ref_035","doi-asserted-by":"crossref","unstructured":"Pato E, Srougi V, Zerbini C, Ledesma FL, Tanno F, Almeida MQ, et al. Clinical and pathological predictors of death for adrenocortical carcinoma. J Endocr Soc 2024; 8: 1-6. doi: 10.1210\/jendso\/bvad170","DOI":"10.1210\/jendso\/bvad170"},{"key":"2026071215424734944_j_raon-2025-0013_ref_036","doi-asserted-by":"crossref","unstructured":"Mete O, Gucer H, Kefeli M, Asa SL. Diagnostic and prognostic biomarkers of adrenal cortical carcinoma. Am J Surg Pathol 2018; 42: 201-13. doi: 10.1097\/PAS.0000000000000943","DOI":"10.1097\/PAS.0000000000000943"},{"key":"2026071215424734944_j_raon-2025-0013_ref_037","doi-asserted-by":"crossref","unstructured":"Giordano TJ. The argument for mitotic rate-based grading for the prognos-tication of adrenocortical carcinoma. Am J Surg Pathol 2011; 35: 471-3. doi: 10.1097\/PAS.0b013e31820bcf21","DOI":"10.1097\/PAS.0b013e31820bcf21"},{"key":"2026071215424734944_j_raon-2025-0013_ref_038","doi-asserted-by":"crossref","unstructured":"Martins-Filho SN, Almeida MQ, Soares I, Wakamatsu A, Alves VAF, Fragoso MCBV, et al. Clinical impact of pathological features including the Ki-67 labeling index on diagnosis and prognosis of adult and pediatric adreno-cortical tumors. Endocr Pathol 2021; 32: 288-300. doi: 10.1007\/s12022-020-09654-x","DOI":"10.1007\/s12022-020-09654-x"},{"key":"2026071215424734944_j_raon-2025-0013_ref_039","doi-asserted-by":"crossref","unstructured":"Morimoto R, Satoh F, Murakami O, Suzuki T, Abe T, Tanemoto M, et al. Immunohistochemistry of a proliferation marker Ki67\/MIB1 in adrenocorti-cal carcinomas: Ki67\/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinoma. Endocr J 2008; 55: 49-55. doi: 10.1507\/endocrj.k07-079","DOI":"10.1507\/endocrj.K07-079"},{"key":"2026071215424734944_j_raon-2025-0013_ref_040","doi-asserted-by":"crossref","unstructured":"Luconi M, Cantini G, van Leeuwaarde RS, Roebaar R, Fei L, Propato AP, et al. Prognostic value of microscopic tumor necrosis in adrenal cortical carci-noma. Endocr Pathol 2023; 34: 224-33. doi: 10.1007\/s12022-023-09760-6","DOI":"10.1007\/s12022-023-09760-6"},{"key":"2026071215424734944_j_raon-2025-0013_ref_041","doi-asserted-by":"crossref","unstructured":"Angelousi A, Kyriakopoulos G, Athanasouli F, Dimitriadi A, Kassi E, Aggeli C, et al. The role of immunohistochemical markers for the diagnosis and prognosis of adrenocortical neoplasms. J Pers Med 2021; 11: 208. doi: 10.3390\/jpm11030208","DOI":"10.3390\/jpm11030208"},{"key":"2026071215424734944_j_raon-2025-0013_ref_042","doi-asserted-by":"crossref","unstructured":"Kareem T, Kimler BF, Davis MK, Fan F, Tawfik O. Ki-67 expression in axillary lymph node metastases in breast cancer is prognostically significant. Hum Pathol 2013; 44: 39-46. doi: 10.1016\/j.humpath.2012.05.00","DOI":"10.1016\/j.humpath.2012.05.007"},{"key":"2026071215424734944_j_raon-2025-0013_ref_043","doi-asserted-by":"crossref","unstructured":"Falato C, Lorent J, Tani E, Karlsson E, Wright PK, Bergh J, et al. Ki67 meas-ured in metastatic tissue and prognosis in patients with advanced breast cancer. Breast Cancer Res Treat 2014; 147: 407-14. doi: 10.1007\/s10549-014-3096-2","DOI":"10.1007\/s10549-014-3096-2"},{"key":"2026071215424734944_j_raon-2025-0013_ref_044","doi-asserted-by":"crossref","unstructured":"Tizianel I, Caccese M, Torresan F, Lombardi G, Evangelista L, Crim\u00ec F, et al. The overall survival and progression-free survival in patients with advanced adrenocortical cancer is increased after the multidisciplinary team evalua-tion. Cancers 2022; 14: 3904. doi: 10.3390\/cancers14163904","DOI":"10.3390\/cancers14163904"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2025-0013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T23:07:00Z","timestamp":1783897620000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2025-0013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,2,27]]},"published-print":{"date-parts":[[2025,3,1]]}},"alternative-id":["10.2478\/raon-2025-0013"],"URL":"https:\/\/doi.org\/10.2478\/raon-2025-0013","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}